PL438683A1 - Sól memantyny, sposób jej otrzymywania, kompozycja i zastosowanie - Google Patents

Sól memantyny, sposób jej otrzymywania, kompozycja i zastosowanie

Info

Publication number
PL438683A1
PL438683A1 PL438683A PL43868321A PL438683A1 PL 438683 A1 PL438683 A1 PL 438683A1 PL 438683 A PL438683 A PL 438683A PL 43868321 A PL43868321 A PL 43868321A PL 438683 A1 PL438683 A1 PL 438683A1
Authority
PL
Poland
Prior art keywords
disorder
memantine
salt
syndrome
dementia
Prior art date
Application number
PL438683A
Other languages
English (en)
Other versions
PL244458B1 (pl
Inventor
Edyta Pindelska
Katarzyna Znajdek
Izabela Madura
Original Assignee
Warszawski Uniwersytet Medyczny
Politechnika Warszawska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warszawski Uniwersytet Medyczny, Politechnika Warszawska filed Critical Warszawski Uniwersytet Medyczny
Priority to PL438683A priority Critical patent/PL244458B1/pl
Publication of PL438683A1 publication Critical patent/PL438683A1/pl
Publication of PL244458B1 publication Critical patent/PL244458B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Przedmiotem wynalazku jest sól memantyny, przy czym solą jest antranilan memantyny, w szczególności antranilan memantyny o Wzorze I. Przedmiotem wynalazku jest również sposób otrzymywania soli memantyny, kompozycja ją zawierająca, zastosowanie soli jako leku w tym zastosowanie w profilaktyce lub leczeniu stanu lub choroby wybranych z grupy składającej się z choroby Alzheimera, demencji, zaburzeń lękowych, zespołu Aspergera, autyzmu, zaburzenia dwubiegunowego, zaburzenia dezintegracyjnego, depresji, destrukcyjnego zaburzenia zachowania, dysleksji, zespołu łamliwego chromosomu X, trudności w uczeniu się, zaburzeń kompulsywnych, zaburzeń opozycyjno-buntowniczych zespołu Retta, otępienia naczyniowego, otępienia z ciałami Lewy'ego, schizofrenii, zaburzeń obsesyjno-kompulsywnych, w tym w szczególności choroby Alzheimera.
PL438683A 2021-08-04 2021-08-04 Sól memantyny, sposób jej otrzymywania, kompozycja i zastosowanie PL244458B1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL438683A PL244458B1 (pl) 2021-08-04 2021-08-04 Sól memantyny, sposób jej otrzymywania, kompozycja i zastosowanie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL438683A PL244458B1 (pl) 2021-08-04 2021-08-04 Sól memantyny, sposób jej otrzymywania, kompozycja i zastosowanie

Publications (2)

Publication Number Publication Date
PL438683A1 true PL438683A1 (pl) 2023-02-06
PL244458B1 PL244458B1 (pl) 2024-01-29

Family

ID=85174318

Family Applications (1)

Application Number Title Priority Date Filing Date
PL438683A PL244458B1 (pl) 2021-08-04 2021-08-04 Sól memantyny, sposób jej otrzymywania, kompozycja i zastosowanie

Country Status (1)

Country Link
PL (1) PL244458B1 (pl)

Also Published As

Publication number Publication date
PL244458B1 (pl) 2024-01-29

Similar Documents

Publication Publication Date Title
ATE542818T1 (de) Imidazo- und triazolopyridinverbindungen und verfahren zu deren anwendung
HK1217486A1 (zh) 作爲β-分泌酶抑制剂的全氟化环丙基稠合的1，3-恶嗪-2-胺化合物以及其使用方法
DE602006021645D1 (de) Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
MX2015011313A (es) Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso.
EP4118221A4 (en) COMPOSITIONS AND METHODS FOR PRODUCING 2,5-FURAN DICARBOXYLIC ACID
MY163346A (en) 3,4-dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives useful as inhibitors of beta-secretase (base)
NO20050309L (no) Nye komplekser av fettsyreestere av polyhydroksyalkan- og pyridinkarboksyderivater
MX387729B (es) Derivados de dióxido de 1,4-tiazina y dióxido 1,2,4-tiadiazina como inhibidores de beta-secretasa y métodos de uso.
MX388696B (es) Derivados de oxazina como inhibidores de beta secretasa y metodos de uso.
MX394391B (es) Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso.
EP4139250A4 (en) Method of preparing iodosilanes and compositions therefrom
HRP20120876T1 (hr) Brzo disocirajuä†i antagonisti dopamin 2 receptora
GEAP202215499A (en) Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors
EP4201431A4 (en) INTERMEDIATE FOR PREPARING ANTIBODY-DRUG CONJUGATE (ADC), ITS PREPARATION METHOD AND ITS USE
MX2020007521A (es) Inhibidores de pi4kiii.
EP3600292A4 (en) PROCESSES FOR THE PREPARATION OF TRIAZOLO [4,5 D] PYRIMIDINE DERIVATIVES AND INTERMEDIARIES THEREOF
Ekkers et al. Surface modification using interfacial assembly of the Streptomyces chaplin proteins
MX2022004878A (es) Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos.
MX386618B (es) Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso.
MX388697B (es) Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
EP4538266A4 (en) PROCESS FOR THE PREPARATION OF 5,5'-BISTETRAZOLE-1,1'-DIHYDROXYAMMONIUM DIOLATE
MX2024003015A (es) Nuevos derivados de quinolina.
CO2023011801A2 (es) Formas cristalinas de (4s)–24–cloro–4–etil–73–fluoro–35–metoxi–32,5–dioxo–14–(trifluoro–metil)–32h–6–aza–3(4,1)–piridina–1(1)–[1,2,3]triazola–2(1,2),7(1)–dibencenaheptafano–74–carboxamida
EP4259416C0 (en) SYSTEM AND METHOD FOR MANUFACTURED FIBER-BASED ARTICLES USING STEAM MOLDING
WO2024226545A3 (en) Molecules and methods of use thereof